{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:11:28Z","timestamp":1792023088691,"version":"4.4.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"NIH\/NINDS","award":["UE5NS134521"],"award-info":[{"award-number":["UE5NS134521"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Population-based studies have linked progestin exposure to increased meningioma risk. However, the molecular basis of meningiomas associated with depot medroxyprogesterone acetate (DMPA)\u2014a common injectable contraceptive\u2014remains undefined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed an integrated clinicopathologic and genomic analysis of meningiomas from 10 women with long-term DMPA exposure. Tumors underwent histopathological analysis, targeted sequencing, and DNA methylation profiling. Data were integrated with reference cohorts (Baylor and Heidelberg) and analyzed through classifier assignment, consensus clustering, copy number analysis, differential methylation testing, and dimensionality reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Depot medroxyprogesterone acetate-associated meningiomas were all newly diagnosed, World Health Organization grade 1 tumors with a predilection for the anterior and central skull base (n\u2009=\u20096). Nine patients harbored multiple meningiomas. Four experienced regression of untreated meningiomas following DMPA cessation, while 5 demonstrated stabilization. Histopathology demonstrated relative overrepresentation of metaplastic morphology, an uncommon meningioma subtype. All DMPA-associated meningiomas mapped to benign molecular groups, and most exhibited low copy number alteration burden. Targeted sequencing revealed enrichment for TRAF7 mutations (n\u2009=\u20095), with no NF2 mutations detected. Eight tumors shared consensus cluster identity, with cohesive grouping on principal component analysis and t-distributed stochastic neighbor embedding. No differential methylation was identified at the progesterone receptor locus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Depot medroxyprogesterone acetate-associated meningiomas represent a recognizable phenotype within the broader NF2-wildtype\/TRAF7-enriched spectrum of benign meningiomas, characterized by chromosomal stability, a shared methylation profile, tumor multiplicity, and regression or stabilization following DMPA cessation. While derived from a small single-institution cohort, these findings provide a molecular framework for understanding progestin-associated meningioma biology, reinterpreting epidemiologic literature, and informing population-level risk stratification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noag136","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T11:40:32Z","timestamp":1780746032000},"page":"2182-2196","source":"Crossref","is-referenced-by-count":1,"title":["Genomic hallmarks of depot medroxyprogesterone acetate-associated meningiomas"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7873-6817","authenticated-orcid":false,"given":"Sakibul","family":"Huq","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, University of Pittsburgh Medical Center , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7456-7996","authenticated-orcid":false,"given":"Taylor A","family":"Gatesman","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of Pittsburgh Medical Center , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9120-5970","authenticated-orcid":false,"given":"Hussam","family":"Abou-Al-Shaar","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of Pittsburgh Medical Center , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9299-8864","authenticated-orcid":false,"given":"David R","family":"Raleigh","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California San Francisco , San Francisco, CA,","place":["USA"]},{"name":"Department of Neurological Surgery, University of California San Francisco , San Francisco, CA, (D.R.R.)","place":["USA"]},{"name":"Department of Pathology, University of California San Francisco , San Francisco, CA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8615-6644","authenticated-orcid":false,"given":"Constantinos G","family":"Hadjipanayis","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of Pittsburgh Medical Center , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1959-4625","authenticated-orcid":false,"given":"James C","family":"Bayley","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of Pittsburgh Medical Center , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios A","family":"Zenonos","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of Pittsburgh Medical Center , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5712-9492","authenticated-orcid":false,"given":"Thomas M","family":"Pearce","sequence":"additional","affiliation":[{"name":"Department of Pathology, Division of Neuropathology, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6171-0688","authenticated-orcid":false,"given":"Daniel F","family":"Marker","sequence":"additional","affiliation":[{"name":"Department of Pathology, Division of Neuropathology, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6584-3795","authenticated-orcid":false,"given":"Sameer","family":"Agnihotri","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of Pittsburgh Medical Center , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1594-1722","authenticated-orcid":false,"given":"Paul A","family":"Gardner","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, New York University Langone Medical Center , New York City, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"2026090801525301200_noag136-B1","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1093\/neuonc\/noae082","article-title":"Meningioma: International Consortium on Meningiomas (ICOM) consensus review on scientific advances & treatment paradigms for clinicians, researchers, and patients","volume":"26","author":"Wang","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026090801525301200_noag136-B2","doi-asserted-by":"publisher","first-page":"e383-e391","DOI":"10.1016\/S1470-2045(16)30321-7","article-title":"EANO guidelines for the diagnosis and treatment of meningiomas","volume":"17","author":"Goldbrunner","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026090801525301200_noag136-B3","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026090801525301200_noag136-B4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s11060-023-04253-2","article-title":"The multiomic landscape of meningiomas: a review and update","volume":"161","author":"Wang","year":"2023","journal-title":"J Neurooncol"},{"key":"2026090801525301200_noag136-B5","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noag086","article-title":"Incidental meningiomas have favorable clinical outcomes across molecular classification systems","author":"Nguyen","journal-title":"Neuro Oncol"},{"key":"2026090801525301200_noag136-B6","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s11060-025-05082-1","article-title":"The hormonal nexus in PIK3CA-mutated meningiomas: implications for targeted therapy and clinical trial design","volume":"174","author":"Abikenari","year":"2025","journal-title":"J Neurooncol"},{"key":"2026090801525301200_noag136-B7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11060-010-0386-3","article-title":"Epidemiology and etiology of meningioma","volume":"99","author":"Wiemels","year":"2010","journal-title":"J Neurooncol"},{"key":"2026090801525301200_noag136-B8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/cncr.22783","article-title":"Exogenous hormone use and meningioma risk: what do we tell our patients?","volume":"110","author":"Claus","year":"2007","journal-title":"Cancer"},{"key":"2026090801525301200_noag136-B9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1055\/s-2004-817695","article-title":"Management strategy for meningioma in pregnancy: a clinical study","volume":"13","author":"Kanaan","year":"2003","journal-title":"Skull Base"},{"key":"2026090801525301200_noag136-B10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1515\/med-2017-0029","article-title":"Pathophysiology of meningioma growth in pregnancy","volume":"12","author":"Hortob\u00e1gyi","year":"2017","journal-title":"Open Med"},{"key":"2026090801525301200_noag136-B11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.4103\/jovr.jovr_21_17","article-title":"Regression of giant olfactory groove meningioma and complete visual acuity recovery after discontinuation of cyproterone acetate","volume":"13","author":"Bernat","year":"2018","journal-title":"J Ophthalmic Vis Res"},{"key":"2026090801525301200_noag136-B12","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s00701-015-2532-3","article-title":"Growth stabilization and regression of meningiomas after discontinuation of cyproterone acetate: a case series of 12 patients","volume":"157","author":"Bernat","year":"2015","journal-title":"Acta Neurochir (Wien)"},{"key":"2026090801525301200_noag136-B13","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1007\/s00701-010-0787-2","article-title":"Regression of meningiomas after discontinuation of cyproterone acetate in a transsexual patient","volume":"152","author":"Cebula","year":"2010","journal-title":"Acta Neurochir (Wien)"},{"key":"2026090801525301200_noag136-B14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00701-018-03782-4","article-title":"Combined hormonal influence of cyproterone acetate and nomegestrol acetate on meningioma: a case report","volume":"161","author":"Champagne","year":"2019","journal-title":"Acta Neurochir (Wien)"},{"key":"2026090801525301200_noag136-B15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.17879\/freeneuropathology-2024-5813","article-title":"Regression of multiple intracranial meningiomas after cessation of long-term synthetic progesterone (megestrol) medication: case report and autopsy","volume":"5","author":"AlDoheyan","year":"2024","journal-title":"Free Neuropathol"},{"key":"2026090801525301200_noag136-B16","doi-asserted-by":"publisher","first-page":"814.e7","DOI":"10.1016\/j.wneu.2017.03.013","article-title":"Dramatic shrinkage with reduced vascularization of large meningiomas after cessation of progestin treatment","volume":"101","author":"Kalamarides","year":"2017","journal-title":"World Neurosurg"},{"key":"2026090801525301200_noag136-B17","doi-asserted-by":"publisher","first-page":"n37","DOI":"10.1136\/bmj.n37","article-title":"Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study","volume":"372","author":"Weill","year":"2021","journal-title":"BMJ"},{"key":"2026090801525301200_noag136-B18","doi-asserted-by":"publisher","first-page":"e083981","DOI":"10.1136\/bmj-2024-083981","article-title":"Oral contraceptives with progestogens desogestrel or levonorgestrel and risk of intracranial meningioma: national case-control study","volume":"389","author":"Roland","year":"2025","journal-title":"BMJ"},{"key":"2026090801525301200_noag136-B19","doi-asserted-by":"publisher","first-page":"100928","DOI":"10.1016\/j.lanepe.2024.100928","article-title":"Prolonged use of nomegestrol acetate and risk of intracranial meningioma: a population-based cohort study","volume":"42","author":"Nguyen","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2026090801525301200_noag136-B20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/jnnp-2021-326138","article-title":"Cyproterone acetate and risk of meningioma: a nationwide cohort study","volume":"93","author":"Mikkelsen","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026090801525301200_noag136-B21","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/neuonc\/noaf228","article-title":"Hormonal contraceptives and the risk of meningioma: a Swedish register-based case-control study","volume":"28","author":"Tettamanti","year":"2026","journal-title":"Neuro Oncol"},{"key":"2026090801525301200_noag136-B22","doi-asserted-by":"publisher","first-page":"e16505","DOI":"10.1111\/ene.16505","article-title":"Prolonged use of chlormadinone acetate and risk of intracranial meningioma: a population-based cohort study","volume":"32","author":"Roland","year":"2025","journal-title":"Eur J Neurol"},{"key":"2026090801525301200_noag136-B23","author":"Statistics NCfH","year":"2022"},{"key":"2026090801525301200_noag136-B24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16193362","article-title":"The association between medroxyprogesterone acetate exposure and meningioma","volume":"16","author":"Griffin","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026090801525301200_noag136-B25","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaneurol.2025.3011","article-title":"Depot medroxyprogesterone acetate and risk of meningioma in the US","volume":"82","author":"Xiao","year":"2025","journal-title":"JAMA Neurol"},{"key":"2026090801525301200_noag136-B26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/978-3-031-29750-2_11","article-title":"Genomic landscape of meningiomas","volume":"1416","author":"Wang","year":"2023","journal-title":"Adv Exp Med Biol"},{"key":"2026090801525301200_noag136-B27","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","article-title":"DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis","volume":"18","author":"Sahm","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026090801525301200_noag136-B28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","article-title":"A clinically applicable integrative molecular classification of meningiomas","volume":"597","author":"Nassiri","year":"2021","journal-title":"Nature"},{"key":"2026090801525301200_noag136-B29","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","article-title":"Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities","volume":"54","author":"Choudhury","year":"2022","journal-title":"Nat Genet"},{"key":"2026090801525301200_noag136-B30","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/neuonc\/noac224","article-title":"Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features","volume":"25","author":"Choudhury","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026090801525301200_noag136-B31","doi-asserted-by":"publisher","first-page":"21715","DOI":"10.1073\/pnas.1912858116","article-title":"Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors","volume":"116","author":"Patel","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"2026090801525301200_noag136-B32","doi-asserted-by":"publisher","first-page":"eabm6247","DOI":"10.1126\/sciadv.abm6247","article-title":"Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies","volume":"8","author":"Bayley","year":"2022","journal-title":"Sci Adv"},{"key":"2026090801525301200_noag136-B33","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1365-2559.2008.03075.x","article-title":"Oestrogen receptor status of breast carcinoma: Allred\/H score conversion table","volume":"53","author":"Shousha","year":"2008","journal-title":"Histopathology"},{"key":"2026090801525301200_noag136-B34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/30.1.207","article-title":"Gene expression omnibus: NCBI gene expression and hybridization array data repository","volume":"30","author":"Edgar","year":"2002","journal-title":"Nucleic Acids Res"},{"key":"2026090801525301200_noag136-B35","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"key":"2026090801525301200_noag136-B36","author":"Epignostix"},{"key":"2026090801525301200_noag136-B37","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3978\/j.issn.1000-9604.2013.01.10","article-title":"Clinicopathological analysis of metaplastic meningioma: report of 15 cases in Huashan Hospital","volume":"25","author":"Tang","year":"2013","journal-title":"Chin J Cancer Res"},{"key":"2026090801525301200_noag136-B38","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/neuonc\/nov289","article-title":"Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors","volume":"18","author":"Nikiforova","year":"2016","journal-title":"Neuro Oncol"},{"key":"2026090801525301200_noag136-B39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205230","article-title":"Oncomine\u2122 comprehensive assay v3 vs. Oncomine\u2122 comprehensive assay plus","volume":"13","author":"Vestergaard","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026090801525301200_noag136-B40","doi-asserted-by":"publisher","first-page":"e3025","DOI":"10.7717\/peerj-cs.3025","article-title":"Comprehensive review of dimensionality reduction algorithms: challenges, limitations, and innovative solutions","volume":"11","author":"Wani","year":"2025","journal-title":"PeerJ Comput Sci"},{"key":"2026090801525301200_noag136-B41","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/annonc\/mdx763","article-title":"Progestin-associated shift of meningioma mutational landscape","volume":"29","author":"Peyre","year":"2018","journal-title":"Ann Oncol"},{"key":"2026090801525301200_noag136-B42","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/neuonc\/noae170","article-title":"cIMPACT-NOW update 8: clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas","volume":"27","author":"Sahm","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026090801525301200_noag136-B43","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1126\/science.1233009","article-title":"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark","year":"2013","journal-title":"Science"},{"key":"2026090801525301200_noag136-B44","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00701-021-05005-9","article-title":"Atypical evolution of meningiomatosis after discontinuation of cyproterone acetate: clinical cases and histomolecular characterization","volume":"164","author":"Passeri","year":"2022","journal-title":"Acta Neurochir (Wien)"},{"key":"2026090801525301200_noag136-B45","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/s0010-7824(03)00136-7","article-title":"Depot-medroxyprogesterone acetate injection (Depo-Provera\u00ae): a highly effective contraceptive option with proven long-term safety","volume":"68","author":"Westhoff","year":"2003","journal-title":"Contraception"},{"key":"2026090801525301200_noag136-B46","doi-asserted-by":"publisher","DOI":"10.1227\/neu.0000000000004031","article-title":"Pattern of intracranial meningiomas associated with prolonged DMPA use: systematic review of synthetic progestins and case series of DMPA-Associated intracranial meningiomas","author":"Abou-Al-Shaar","year":".    .","journal-title":"Neurosurgery"},{"key":"2026090801525301200_noag136-B47","doi-asserted-by":"publisher","first-page":"104154","DOI":"10.1016\/j.bas.2024.104154","article-title":"Recommendations on the management of meningioma and sex hormone therapy: the results of a collaborative effort between neurosurgical, endocrine and gynecological societies","volume":"5","author":"Reuter","year":"2025","journal-title":"Brain and Spine"},{"key":"2026090801525301200_noag136-B48","doi-asserted-by":"publisher","first-page":"R385","DOI":"10.1530\/ERC-18-0033","article-title":"Chromatin reprogramming in breast cancer","volume":"25","author":"Swinstead","year":"2018","journal-title":"Endocr Relat Cancer"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag136\/68490686\/noag136.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/9\/2182\/68490686\/noag136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/9\/2182\/68490686\/noag136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:53:05Z","timestamp":1788846785000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/28\/9\/2182\/8703984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,6,8]]},"published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag136","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,6,8]]}}}